These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 30786754)

  • 1. Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
    Ferdinand KC; Izzo JL; Lee J; Meng L; George J; Salsali A; Seman L
    Circulation; 2019 Apr; 139(18):2098-2109. PubMed ID: 30786754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
    Mancia G; Cannon CP; Tikkanen I; Zeller C; Ley L; Woerle HJ; Broedl UC; Johansen OE
    Hypertension; 2016 Dec; 68(6):1355-1364. PubMed ID: 27977392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus.
    Ferdinand KC; Seman L; Salsali A
    Curr Med Res Opin; 2018 Feb; 34(2):361-367. PubMed ID: 29139301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study.
    Kario K; Okada K; Kato M; Nishizawa M; Yoshida T; Asano T; Uchiyama K; Niijima Y; Katsuya T; Urata H; Osuga JI; Fujiwara T; Yamazaki S; Tomitani N; Kanegae H
    Circulation; 2019 Apr; 139(18):2089-2097. PubMed ID: 30586745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
    Tikkanen I; Narko K; Zeller C; Green A; Salsali A; Broedl UC; Woerle HJ;
    Diabetes Care; 2015 Mar; 38(3):420-8. PubMed ID: 25271206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
    Chilton R; Tikkanen I; Cannon CP; Crowe S; Woerle HJ; Broedl UC; Johansen OE
    Diabetes Obes Metab; 2015 Dec; 17(12):1180-93. PubMed ID: 26343814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
    Chilton R; Tikkanen I; Hehnke U; Woerle HJ; Johansen OE
    Diabetes Obes Metab; 2017 Nov; 19(11):1620-1624. PubMed ID: 28387058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
    Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.
    Neutel JM; Kereiakes DJ; Waverczak WF; Stoakes KA; Xu J; Shojaee A
    Curr Med Res Opin; 2010 Mar; 26(3):721-8. PubMed ID: 20085534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
    Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
    Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
    Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
    Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
    Zinman B; Inzucchi SE; Lachin JM; Wanner C; Fitchett D; Kohler S; Mattheus M; Woerle HJ; Broedl UC; Johansen OE; Albers GW; Diener HC;
    Stroke; 2017 May; 48(5):1218-1225. PubMed ID: 28386035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Connelly KA; Mazer CD; Puar P; Teoh H; Wang CH; Mason T; Akhavein F; Chang CW; Liu MH; Yang NI; Chen WS; Juan YH; Opingari E; Salyani Y; Barbour W; Pasricha A; Ahmed S; Kosmopoulos A; Verma R; Moroney M; Bakbak E; Krishnaraj A; Bhatt DL; Butler J; Kosiborod MN; Lam CSP; Hess DA; Rizzi Coelho-Filho O; Lafreniere-Roula M; Thorpe KE; Quan A; Leiter LA; Yan AT; Verma S
    Circulation; 2023 Jan; 147(4):284-295. PubMed ID: 36335517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.
    Jürgens M; Schou M; Hasbak P; Kjær A; Wolsk E; Zerahn B; Wiberg M; Brandt-Jacobsen NH; Gæde P; Rossing P; Faber J; Inzucchi SE; Gustafsson F; Kistorp C
    J Am Heart Assoc; 2021 Aug; 10(15):e020418. PubMed ID: 34278803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Fitchett D; Ofstad AP; Kraus BJ; Wanner C; Zwiener I; Zinman B; Lauer S; George JT; Rossignol P; Zannad F
    Am J Hypertens; 2020 Dec; 33(12):1092-1101. PubMed ID: 32369546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.